☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
MSI-H mCRC
BMS' Opdivo (nivolumab) + Yervoy (ipilimumab) Receive EC's Approval for dMMR or MSI-H mCRC After Prior Chemotherapy
June 30, 2021
BMS Receive the CHMP's Positive Opinion Recommending Approval of Opdivo (nivolumab) + Yervoy (ipilimumab) for dMMR or MSI-H mCRC A...
May 24, 2021
Load more...
Back to Home
Modal title
×
Modal body text goes here.